# US 7,745,387 B2 · Use of erythropoietin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,387 B2
- Document ID: US7745387B2
- Status: Granted
- Kind: B2
- Application number: 10/522,426
- Filed: 2003-07-25
- Published: 2005-12-08
- Granted: 2010-06-29
- Earliest claimed: 2002-07-26
- Assignees: Epoplus GmbH & Co. KG
- Inventors: Ferdinand Hermann Bahlmann; Hermann Haller
- Web page: https://patentgrep.com/patent/US7745387B2

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.

## Claims

### Claim 1

A method for diabetic wound healing, said method comprising administering a pharmaceutical composition comprising a subpolycythemic erythropoietin weekly dose of 1 to 90 international units (IU) EPO/kg body weight to a subject in need of said wound healing for healing of said diabetic wound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered parenterally.

### Claim 3 (depends on 2)

The method of claim 2, wherein said parenteral administration is carried out using a mode selected from the group consisting of intravenous, intramuscular, intracutaneous and subcutaneous, administration.

### Claim 4 (depends on 1)

The method of claim 1, where the pharmaceutical composition is administered via pulmonary administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is orally administered.

### Claim 6 (depends on 1)

The method of claim 1, where the pharmaceutical composition comprises at least one further active ingredient which stimulates endothelial progenitor cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the erythropoietin is human or animal erythropoietin.